NasdaqCM - Delayed Quote • USD
Genelux Corporation (GNLX)
At close: 4:00 PM EDT
After hours: 6:29 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -0.23 | -0.23 | -0.93 | -1.15 |
| Low Estimate | -0.26 | -0.26 | -1.03 | -1.39 |
| High Estimate | -0.21 | -0.21 | -0.84 | -0.91 |
| Year Ago EPS | -0.53 | -0.23 | -1.16 | -0.93 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | 170k | -- | 170k | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.16 | -0.15 | -0.18 | -0.19 |
| EPS Actual | -0.53 | -0.23 | -0.2 | -0.25 |
| Difference | -0.37 | -0.08 | -0.02 | -0.06 |
| Surprise % | -231.20% | -53.30% | -11.10% | -31.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.23 | -0.23 | -0.93 | -1.15 |
| 7 Days Ago | -0.23 | -0.23 | -0.93 | -1.15 |
| 30 Days Ago | -0.21 | -0.21 | -0.85 | -1.21 |
| 60 Days Ago | -0.23 | -0.23 | -0.91 | -1.28 |
| 90 Days Ago | -0.23 | -0.23 | -0.91 | -1.28 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | GNLX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 56.60% | -- | -- | 1.50% |
| Next Qtr. | 0.00% | -- | -- | 11.40% |
| Current Year | 19.80% | -- | -- | 5.20% |
| Next Year | -23.70% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Benchmark: Speculative Buy to Speculative Buy | 4/3/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 4/2/2024 |
| Initiated | HC Wainwright & Co.: Buy | 11/27/2023 |
| Maintains | Benchmark: Speculative Buy to Speculative Buy | 11/24/2023 |
| Initiated | Maxim Group: Buy | 9/12/2023 |
| Maintains | Benchmark: Speculative Buy to Speculative Buy | 6/9/2023 |
Related Tickers
CGON CG Oncology, Inc.
36.05
-0.72%
REPL Replimune Group, Inc.
6.33
-1.40%
CRGX CARGO Therapeutics, Inc.
18.75
-1.32%
LOBEF Lobe Sciences Ltd.
0.0146
+1.39%
CVKD Cadrenal Therapeutics, Inc.
0.4284
+0.45%
ERAS Erasca, Inc.
1.8800
-2.59%
NAMS NewAmsterdam Pharma Company N.V.
21.80
+1.63%
FBLG FibroBiologics, Inc.
11.52
+3.78%
ABVX ABIVAX Société Anonyme
15.89
-0.69%
ANRO Alto Neuroscience, Inc.
14.20
+2.31%